<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109243">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01886664</url>
  </required_header>
  <id_info>
    <org_study_id>Des vs Sevo PRS</org_study_id>
    <nct_id>NCT01886664</nct_id>
  </id_info>
  <brief_title>Comparison of PRS According to Inhalation Agent During LDLT</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators tried to evaluate the effect of desflurane on the incidence of
      postreperfusion syndrome during living donor liver transplantation surgery. The
      investigators used sevoflurane as a comparison.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>frequency of PRS</measure>
    <time_frame>immediately after reperfusion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>reperfusion syndrome occurs, if it occurs, immediately after reperfusion. Therefore, the primary outcome, reperfusion syndrome, can only be assessed immediately after reperfusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>after LT until the patient is transferred to the ward</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Liver Transplantation</condition>
  <condition>Postreperfusion Syndrome</condition>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Performing liver transplantation under general anesthesia using sevoflurane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Performing liver transplantation under general anesthesia using desflurane</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevoflurane</intervention_name>
    <arm_group_label>Sevoflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desflurane</intervention_name>
    <arm_group_label>Desflurane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective LDLT

        Exclusion Criteria:

          -  age &lt; 18, age &gt; 65

          -  patient refusal

          -  re-transplantation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ho Geol Ryu, MD</last_name>
    <phone>82220722065</phone>
    <email>hogeol@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiwon Lee, MD</last_name>
      <phone>82220723283</phone>
      <email>belief705@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 21, 2013</lastchanged_date>
  <firstreceived_date>August 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Desflurane</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
